Medvi Review 2026: Tirzepatide, Semaglutide, and the Real Cost

What does Medvi actually sell?

The ads make Medvi look like a single product — a dissolving tirzepatide tablet, no needle, mailed to your door. The real catalog is wider than that. Medvi compounds both tirzepatide and semaglutide, and offers each one as either a daily oral tablet or a weekly injection, so the tablet you saw in the ad is one of four compounded options, not the whole business. On top of that compounded menu, Medvi runs a separate membership track that brokers access to the FDA-approved brand-name drugs themselves — Zepbound as an injection, Wegovy as either a pill or an injection — for patients who specifically want the manufactured product rather than a pharmacy-compounded version.

That split matters more than it sounds like it should. Medvi itself doesn't compound anything, employ the prescribers, or own a pharmacy — it's the intake and marketing layer sitting on top of a stack of outside vendors: OpenLoop Health supplies the licensed clinicians who review your intake and write the prescription, and Belmar Pharma Solutions, a national 503A/503B compounding operator, fills the compounded tablets and injections. That's a common structure in GLP-1 telehealth — plenty of competitors outsource clinical infrastructure the same way — but it's worth knowing you're dealing with several linked companies, not one vertically integrated clinic, if something goes wrong with billing or a prescription.

Is Medvi legitimate and safe to use?

Yes, in the sense that matters most: Medvi runs a genuine medical intake, routes your case to a licensed prescriber before anything ships, and dispenses through a named, licensed compounding pharmacy rather than an anonymous supplement warehouse. That's a meaningfully different thing from a scam selling an unregulated substance with no clinical process behind it.

The FDA warning letter, explained

It's also a company the FDA has already flagged once. On February 20, 2026, the agency sent Medvi a warning letter over website language stating its compounded products contained the "same active ingredient as Wegovy® and Ozempic®" and "same active ingredient as Mounjaro® and Zepbound®." The FDA's objection was that phrasing implies the compounded versions had been evaluated and approved the way the brand-name drugs were — they hadn't — and the agency separately noted that Medvi's name appeared on pictured product labels in a way that suggested Medvi itself was the compounder, when the actual compounding is done by its pharmacy partner. Medvi wasn't singled out: the FDA sent similar letters to more than 30 telehealth companies the following month over comparable marketing language, which is useful context — this reads as an industry-wide labeling sweep, not evidence that Medvi's medication itself is fake.

Worth naming too: independent reporting (Futurism, 2025) found AI-generated marketing content, including fabricated testimonials, on Medvi's site — a reason to treat Medvi's own ad copy skeptically and verify pricing independently, even though real prescribers and a real pharmacy sit behind the transaction.

What does Medvi really cost — not just the ad price?

Medvi's ads lead with a discounted first month, commonly reported around $279 regardless of medication or format. That's not the number to budget against. After the first month, compounded semaglutide settles at roughly $299 monthly, with lower starting-dose tiers reported as low as $179 and a discounted rate near $249 available on prepaid multi-month plans. Compounded tirzepatide runs higher, converging around $399 monthly ongoing, with higher maintenance-dose tiers reported climbing toward $449 to $499. No source differentiates tablet pricing from injection pricing within the same medication — the format choice appears to be free once you've picked semaglutide or tirzepatide.

The compounded plans carry no separate membership fee — the monthly price is meant to cover the provider visit, the medication, and shipping. The brand-name track works differently: access to Zepbound or Wegovy runs through a $99 monthly membership, with the medication itself billed separately at its own cash price, which for either brand typically runs well above the compounded tirzepatide ceiling. Budget for that gap deliberately if brand-name is the reason you're considering Medvi in the first place — the membership fee is the smaller number on that path, not the total.

How the Medvi process actually works

The flow is standard for compounded GLP-1 telehealth, with a short list of steps between the ad and the medication showing up at your door.

• Complete an online health questionnaire covering weight history, medical conditions, and current medications — this is also where dose-specific pricing appears, which is why the exact ongoing rate isn't posted upfront on the marketing pages
• A licensed provider in the OpenLoop Health network reviews your intake and, if appropriate, writes a prescription for compounded semaglutide, compounded tirzepatide, or a brand-name alternative
• The prescription routes to Belmar Pharma Solutions, a 503A/503B compounding pharmacy network, for the compounded plans, or to a separate pharmacy channel for brand-name Zepbound or Wegovy
• Medication ships directly to your address, with the tablet or injection format chosen during intake
• Ongoing provider access is available for dose adjustments and follow-up questions
• Coverage currently extends to 49 states, with Mississippi excluded — confirm your specific state during intake, since telehealth prescribing rules shift

What do real Medvi customers say?

The reputation picture is genuinely mixed rather than uniformly good or bad, and it splits cleanly by platform. On Trustpilot, Medvi holds roughly 4.4 out of 5 across more than 11,000 reviews, with the large majority five-star and recurring praise for weight-loss results, responsive providers, and price relative to brand-name drugs. ConsumerAffairs tells a rougher story, with a rating closer to 3.6 out of 5 and billing as the dominant complaint theme — charges continuing after a requested pause, and refund requests met with generic policy responses rather than individual review. The Better Business Bureau rates Medvi an F, unaccredited, citing 726 total complaints and a failure to respond to 128 of them as the reason for the grade — a genuinely poor complaint-handling record worth weighing directly against the much more positive Trustpilot picture, not a single verdict to average away.

Medvi's name also appears in litigation, though not as the central figure. It's one of several consumer-facing telehealth platforms named in a broader class action tied to its clinician network, and a separate complaint filed in early 2026 remains undecided — allegations at this stage, not adjudicated findings. Reddit sentiment in weight-loss communities skews similar to the ConsumerAffairs pattern more than the Trustpilot one: real weight loss reported by users who stuck with the program, alongside recurring skepticism about the company's marketing claims and billing practices. None of that is unique to Medvi in this category, but it's consistent enough across sources to take seriously rather than dismiss as noise.

Medvi vs. Zepbound and other GLP-1 telehealth names

The comparison that shows up most in search is Medvi against Zepbound, Eli Lilly's FDA-approved tirzepatide injection — and the honest short version is that it's not really an apples-to-apples price comparison, it's a regulatory one. Zepbound went through full FDA review as a finished drug; Medvi's compounded tirzepatide, tablet or injection, is prepared by a licensed pharmacy under an individual prescription rather than manufactured and reviewed the same way. The full dollar-by-dollar comparison lays out both companies' current pricing tiers side by side, including Zepbound's LillyDirect self-pay ladder and savings-card options that have no equivalent on Medvi's compounded plans.

Against other compounded GLP-1 telehealth names, Medvi's four-way compounded menu — tablet and injection, semaglutide and tirzepatide — is genuinely broader than most single-format competitors, and its discounted first month is one of the lower entry points in the category. Henry Meds runs a comparable all-in bundled model with no separate membership fee and a similar oral-and-injectable menu, minus Medvi's brand-name broker option and its FDA warning letter. Mochi Health leans harder on obesity-medicine credentialing, requiring ABOM-certified physicians across its network, which Medvi does not specifically advertise. Ro sits closer to the brand-name end of the spectrum, with a stronger emphasis on getting patients onto Zepbound or Wegovy through insurance where possible rather than defaulting to a compounded product. If tablet absorption is your specific concern with any compounded oral tirzepatide, including Medvi's, the pills and patches legitimacy breakdown covers the evidence gap in more depth than fits here — no compounder, Medvi included, has published human absorption data for an oral tirzepatide tablet the way Rybelsus has for oral semaglutide.

Who Medvi is right for — and who should look elsewhere

Medvi fits a specific, fairly common profile: someone comfortable with a compounded medication, prioritizing entry price and format flexibility over brand-name certainty, who's willing to do a little of their own diligence before trusting the marketing copy.

• Cost-driven and compounded-comfortable — the discounted first month and roughly $299-399 ongoing range beat most brand-name self-pay tiers, and Medvi is upfront that the product is compounded, not the FDA-approved brand
• Wants format choice without switching providers — tablet or injection, semaglutide or tirzepatide, all under one intake
• Specifically wants brand-name Zepbound or Wegovy but likes the idea of one platform — the $99/mo membership track exists for exactly this, though it's worth pricing against going directly to Zepbound or a pharmacy benefit instead
• Needle-averse and willing to accept the tablet's thinner evidence base — Medvi's oral option is real medication, just one without published absorption data behind it
• Better served elsewhere: patients who want ABOM-certified obesity-medicine specialists specifically (Mochi Health), a single flat all-in fee with zero billing ambiguity (Henry Meds), or a company with a cleaner BBB and litigation record and no active FDA warning letter

How to enroll — and what to check first

The intake itself is quick, but the diligence worth doing happens before you hand over a card number, not after.

• Get your specific medication, format, and dose's ongoing monthly price in writing before your first shipment — the ad's discounted first-month figure is not what you'll pay long-term
• Confirm your state is covered — reported as 49 states with Mississippi excluded, but state telehealth rules shift, so verify directly during intake
• Ask which pharmacy is filling your specific prescription and confirm it holds current state licensure, since compounding is handled by a partner pharmacy, not Medvi itself
• If billing is a concern going in, read the recent ConsumerAffairs and BBB complaint patterns first — most center on charges continuing after a cancellation request
• If you specifically want FDA-approved Zepbound or Wegovy rather than a compounded version, price Medvi's $99/mo membership track against going straight to the manufacturer's own self-pay program before assuming Medvi is the cheaper route